News & Updates

Among treatment-naïve patients with HIV-1* infection, initial treatment combination with doravirine and islatravir (DOR/ISL) was noninferior in achieving virologic suppression (HIV-1 RNA <50 copies/mL) at week 48 compared with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), according to a trial presented at IAS 2023.

Nightly administration of atropine 0.01% eye drops does little to slow myopia progression or axial elongation in a cohort of school-aged children in the US who have low-to-moderate myopia, as shown in a study.

The Malaysian Pharmacists Society (MPS) recently hosted the National Pharmacists Convention 2023 in Subang Jaya, with more than 350 delegates from various sectors and areas of practice, including community, academia, public health, and military pharmacy to shape the future of pharmacy and healthcare in Malaysia.

Misoprostol alone appears to be safe and effective for termination of first trimester pregnancy and can be used if mifepristone is unavailable or inaccessible, according to a study.

In women with heavy menstrual bleeding, treatment with levonorgestrel intrauterine system is as good as combined oral contraceptives, with both strategies improving bleeding-related quality of life, as reported in a study.

New immune-related adverse events (irAEs) start to appear more than 6 months following completion of selective immunosuppressive therapy (SIT) agents, such as infliximab and vedolizumab, for initial colitis events, reports a study.